Larvol Delta - Topline-data-from-the-LUMUS-Phase-2b-trial-of-envudeucitinib-in-systemic-lupus-erythematosus-is-expected-in-the-third-quarter-of-2026

envudeucitinib (ESK-001) - Alumis

https://www.globenewswire.com/news-release/2026/08/10/3342219/0/en/envudeucitinib-long-term-data-positioned-to-set-a-new-standard-for-plaque-psoriasis-treatment-delivering-highest-reported-pasi-100-skin-clearance-among-oral-therapies.html

Aug 10, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next